Multicentre evaluation of artificial intelligence risk classification for detection of clinically significant prostate cancer on biparametric MRI - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Multicenter Assessment of AI-Based Risk Stratification for Identifying Clinically Relevant Prostate Cancer via Biparametric MRI

  • By

  • Karsten Guenzel

  • Maarten G. Poirot

  • Almar van Loon

  • Emanuele Messina

  • Martina Pecoraro

  • Valeria Panebianco

  • Robert Princenthal

  • Francesco Giganti

  • September 26, 2026

Share

  • 1

    The study assessed AI-based risk classification for clinically significant prostate cancer detection using biparametric MRI.

  • 2

    Participants included men aged ≥ 18 years who underwent prostate MRI followed by biopsy or prostatectomy across three cohorts.

  • 3

    The reference standard for detection was histopathology obtained through targeted and systematic biopsy or prostatectomy.

  • 4

    AI-derived risk categorization was compared to radiologist-assigned PI-RADS for clinically significant prostate cancer detection.

  • 5

    The study aimed to evaluate the utility of AI in managing equivocal lesions categorized as PI-RADS 3.

Original Source(s)

Multicentre evaluation of artificial intelligence risk classification for detection of clinically significant prostate cancer on biparametric MRI

  • by Karsten Guenzel, Maarten G. Poirot, Almar van Loon, Emanuele Messina, Martina Pecoraro, Valeria Panebianco, Robert Princenthal, Francesco Giganti

  • September 26, 2026

Related Content

Beyond classical boundaries: rethinking ICU access in acute leukemia

Decoding cancer-associated ribosomal protein mutations: A new frontier in cancer and ribosome biology

Malignant transformation of lower-grade glioma: contrast enhancement, extent of resection, and the natural history under interval-censored analysis